23andMe 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12»
  • ||||||||||  GSK4381562 / GSK
    Trial completion date, Trial primary completion date, Monotherapy:  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 12, 2024   
    P1,  N=141, Recruiting, 
    Recruiting --> Completed | Trial completion date: Jul 2025 --> May 2024 | Trial primary completion date: Jul 2025 --> May 2024 Trial completion date: Oct 2026 --> Sep 2028 | Trial primary completion date: Oct 2026 --> Sep 2028
  • ||||||||||  23ME-00610 / 23andMe
    Trial completion date, Trial primary completion date, Tumor mutational burden:  23ME-00610-CLIN-001: A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) -  May 22, 2024   
    P1/2,  N=141, Active, not recruiting, 
    Trial completion date: Aug 2027 --> May 2027 | Trial primary completion date: Sep 2025 --> May 2027 Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
  • ||||||||||  23ME-00610 / 23andMe
    New insights into targeting the CD200R1 pathway in T and NK cells using 23ME-00610 as a single agent or in combination (Section 38) -  Mar 5, 2024 - Abstract #AACR2024AACR_3752;    
    P1/2
    Taken together, these data demonstrate that 23ME-00610 can enhance both NK and T cell antitumor effector functions, and 23ME-00610 could synergize with anti-PD-1 to further increase the activity of T cells against cancer cells. The results of this study provide evidence that 23ME-00610 could expand IO treatment options for patients with advanced solid malignancies as a single agent or in combination with other anti-tumor therapeutics.
  • ||||||||||  nelistotug (GSK6097608) / GSK
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Oct 31, 2023   
    P1,  N=244, Recruiting, 
    Trial completion date: Mar 2026 --> Jan 2028 N=184 --> 244 | Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025
  • ||||||||||  GSK4381562 / GSK
    Trial completion date, Trial primary completion date, Monotherapy:  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 14, 2023   
    P1,  N=162, Recruiting, 
    Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
  • ||||||||||  nelistotug (GSK6097608) / GSK
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 23, 2023   
    P1,  N=184, Recruiting, 
    Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026 Trial completion date: Apr 2025 --> Jul 2024 | Trial primary completion date: Apr 2025 --> Jul 2024
  • ||||||||||  nelistotug (GSK6097608) / GSK
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 4, 2023   
    P1,  N=184, Recruiting, 
    Trial completion date: Apr 2025 --> Jul 2024 | Trial primary completion date: Apr 2025 --> Jul 2024 Trial completion date: Aug 2024 --> Apr 2025 | Trial primary completion date: Aug 2024 --> Apr 2025
  • ||||||||||  GSK4381562 / GSK
    Trial completion date, Trial primary completion date, Monotherapy:  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 23, 2022   
    P1,  N=162, Recruiting, 
    Phase classification: P1 --> P1/2 | N=105 --> 148 Trial completion date: Feb 2027 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
  • ||||||||||  nelistotug (GSK6097608) / GSK
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 18, 2022   
    P1,  N=178, Recruiting, 
    Part 1 endpoints are safety and tolerability (primary) and efficacy and pharmacokinetics (secondary). Trial completion date: Feb 2023 --> Aug 2024 | Trial primary completion date: Feb 2023 --> Aug 2024
  • ||||||||||  GSK4381562 / GSK
    Enrollment open, Trial completion date, Trial primary completion date, Monotherapy:  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 3, 2022   
    P1,  N=126, Recruiting, 
    Trial completion date: Feb 2023 --> Aug 2024 | Trial primary completion date: Feb 2023 --> Aug 2024 Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Feb 2027 | Trial primary completion date: Feb 2023 --> Oct 2024
  • ||||||||||  nelistotug (GSK6097608) / GSK
    Enrollment change, Combination therapy, Monotherapy, Metastases:  Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 24, 2021   
    P1,  N=148, Recruiting, 
    Taken together, these results demonstrate that 23ME-00610 has the potential to reverse CD200-mediated immunosuppression in the TME to enhance anti-tumor T-cell functions in cancer patients. N=111 --> 148